ThromboGenics NV: Positive Microplasmin Phase II Data Published in Ophthalmology
2/9/2010
More...
|
Kamada Ltd. Announces Enrollment of First Patient in Its Pivotal Study for Inhaled AAT in Europe
2/8/2010
More...
|
Clinical Trial Delays Hit Lipoxen (LPX.L) Revenues
2/5/2010
More...
|
Hybrigenics Receives Positive Answers From European Medicines Evaluation Agency on Clinical Phase IIb Efficacy Study
2/3/2010
More...
|
Vantia Therapeutics' Lead Candidate VA106483 Enters Phase IIb Trial for Nocturia
2/2/2010
More...
|
Ark Therapeutics: First Refractory Angina Patient Treated with VEGF-D shortform (EG011) in Phase I/IIa Trial
2/2/2010
More...
|
Synosia Therapeutics Announces Positive Interim Results for Potential First-in-Class Treatment for Parkinson's Disease
2/1/2010
More...
|
Lipid Therapeutics Announces Start of Phase IIb Clinical Trial
1/29/2010
More...
|
BTG plc (BGC.L) Commences Phase IIa Study of Pleneva(TM) for Multiple Sclerosis
1/21/2010
More...
|
MorphoSys AG Enrolls First Patient in Phase 1b/2a Clinical Trial for MOR103 Program in Rheumatoid Arthritis
1/19/2010
More...
|
Oramed Pharmaceuticals Inc. (ORMP.OB) Announces Completion of Patient Enrollment for Pivotal Phase 2B Clinical Trials of ORMD-0801
1/19/2010
More...
|
Circassia Limited Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
1/19/2010
More...
|
AVIR Green Hills Biotechnology AG: Start of Phase II Study for Intranasal, Seasonal Influenza Vaccine deltaFLU
1/13/2010
More...
|
Cytheris SA Initiates INSPIRE 2, a Phase II Clinical Trial of Recombinant Human Interleukin-7 (CYT107) in Chronically Infected HIV Patients Who Fail to Achieve Optimal Immune Reconstitution under HAART Therapy
1/12/2010
More...
|
Apogenix Initiates Clinical Phase II Study with its Lead Compound APG101 in Glioblastoma
1/11/2010
More...
|
Hybrigenics Receives Authorization To Dose Prostate Cancer Patients Twice Daily With Oral Inecalcitol
1/6/2010
More...
|
VBL Therapeutics Initiates Phase 2 Clinical Trial of VB-201 in Patients with Psoriasis
1/5/2010
More...
|
Immutep S.A. Announces Final Results In Phase I/II Chemoimmunotherapy Trial In Breast Cancer
1/4/2010
More...
|
NovaBiotics Ltd Successful Completion of Phase IIa Clinical Development of its Nail Fungus Treatment, Novexatin(R)
1/4/2010
More...
|
Flamel Technologies (FLML) Announces the Initiation of a Phase 2a Clinical Trial of Flamel's IFN-Alpha-2b XL in Patients with Chronic Hepatitis C Virus Infection
12/18/2009
More...
|
BioAlliance Pharma: Entry into Clinical Phase: Clonidine Lauriad(R) into Phase II and AMEP(TM) into Phase I
12/15/2009
More...
|
Can-Fite BioPharma to Initiate Phase II Clinical Trial with CF101 for the Treatment of Glaucoma
12/15/2009
More...
|
KeyNeurotek Pharmaceuticals Reports Breakthrough In The Treatment Of Patients With Severe Traumatic Brain Injury In A Phase IIa Study
12/14/2009
More...
|
Addex Pharmaceuticals (ADXN.SW) Stops Lead Drug Trial Due To Liver Problems
12/14/2009
More...
|
Primary Endpoint Reached In Active Biotech AB's TASQ Phase II Clinical Trial In Prostate Cancer Patients
12/14/2009
More...
|
Ariad Pharmaceuticals, Inc. (ARIA) Announces Updated Data from Clinical Trial of Its Investigational mTOR Inhibitor, Ridaforolimus, In Combination with Trastuzumab
12/14/2009
More...
|
Cosmo Pharmaceuticals S.p.A.'s CB-03-01 Phase II Pilot Study In Acne Demonstrates Superiority Over Retin A(R)
12/11/2009
More...
|
ThromboGenics NV Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
12/11/2009
More...
|
Knopp NeuroSciences Reports Presentation of Encouraging Clinical Trends in a Phase 2 Study of KNS-760704 in ALS
12/9/2009
More...
|
Oxagen Limited Announces Completion of Recruitment in Phase IIb Dose Range-Finding Clinical Trial in New Oral Treatment for Asthma
12/9/2009
More...
|
Cytheris SA Announces Initiation of CONVERT, a Phase I/IIa Study of Recombinant Human Interleukin-7 (CYT107) in Combination with Antiviral Therapy and Vaccination for Treatment of Chronic Hepatitis B Virus
12/8/2009
More...
|
Neovacs SA Initiates a Phase II Clinical Trial of TNFa Kinoid in Rheumatoid Arthritis Patients Failing TNFa Monoclonal Antibody Therapy
12/8/2009
More...
|
Gentium S.p.A. Announces Final Clinical Trial Results for Defibrotide Presented at the American Society of Hematology Conference
12/8/2009
More...
|
BioAlliance Pharma: Doxorubicin Transdrug(R): Significant Increased Survival Rate In Patients With Advanced Hepatocellular Carcinoma Treated In A Phase II Clinical Trial
12/8/2009
More...
|
Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine
12/7/2009
More...
|
Celgene International Sárl (CELG): Phase II Data Evaluating REVLIMID(R) + Rituximab in Relapsed Patients with Chronic Lymphocytic Leukaemia Presented at American Society of Hematology
12/7/2009
More...
|
Antisoma PLC (ASM.L)'s AS1413 Regimen Yields High Response Rate And Durable Responses In Patients With Secondary AML, A Poor-Risk Population Underserved By Current Treatment Options
12/7/2009
More...
|
Clavis Pharma ASA: Positive Phase II Clinical Data For Clavis Pharma's Elacytarabine Presented At American Society of Hematology Annual Meeting
12/7/2009
More...
|
Q-Med AB and Oceana Therapeutics Take Major Step Towards SOLESTA(TM) US Regulatory Filing
12/7/2009
More...
|
PharmaSurgics to Begin Phase II Clinical Trial for Prevention of Post-Surgical Adhesions
12/3/2009
More...
|
Lightlake Therapeutics Inc. Receives Ethical Approval to Begin Subject Selection for Future Phase II Clinical Trial for New Obesity Drug, in Helsinki, Finland
12/3/2009
More...
|
Optinose Announces Study Results Of Intranasal Device For Treating Chronic Rhinosinusitis With Nasal Polyps
12/2/2009
More...
|
Dermagen Inc. Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
12/2/2009
More...
|
Agennix AG Announces Positive Results With Talactoferrin in Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial in Severe Sepsis
12/1/2009
More...
|
Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) ATIR(TM) for Reduction of Transplant Related Mortality Following an Allogeneic Stem Cell Transplantation Using a Mismatched Donor
11/30/2009
More...
|
Biovitrum AB's Kiobrina(TM) Shows Positive Phase II Results In Preterm Infants
11/25/2009
More...
|
Ipsen Initiates an Advanced Endometrial Cancer Program with BN83495, its First-in-Class Steroid Sulfatase (STS) Inhibitor
11/25/2009
More...
|
Cytheris SA Announces Initiation of National Cancer Institute/National Institutes of Health (NIH) Sponsored Phase I/IIa Clinical Study of Tumor Vaccination and Interleukin-7 (IL-7) in Patients with High Risk Pediatric Solid Tumors
11/23/2009
More...
|
GENFIT Corp. (ALGFT): Extremely Promising Gft505 Results In Phase II
11/23/2009
More...
|
Moberg Derma Reports Positive Phase II Results For K201 Against Atopic Eczema
11/20/2009
More...
|
Medivir AB (MVIRb.F): Epiphany Biosciences, Inc. Announces Positive Results from Its Phase 2b Trial in Shingles
11/19/2009
More...
|
Mesoblast Limited Sustained Six-Month Improvement In Heart Muscle Function With Revascor, "Off-The-Shelf" Adult Stem Cells
11/18/2009
More...
|
Neovacs SA Release: Preliminary Clinical Results From The Phase I/II Trial Of Tnfa Kinoid In Crohn’s Disease To Be Presented At GASTRO 2009 In London
11/18/2009
More...
|
Galapagos NV (GLPG.BR) Initiates Nanocort(R) Phase II Clinical Trial For Multiple Sclerosis
11/17/2009
More...
|
Addex Pharmaceuticals (ADXN.SW) ADX10059 Monotherapy is Effective on GERD Symptoms in Phase IIb Clinical Trial
11/16/2009
More...
|
Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
11/13/2009
More...
|
Viron Therapeutics Inc. to Present Data from Phase II Trial at American Heart Association Conference
11/12/2009
More...
|
Tripep: Interim Analysis of ChronSeal(R)
11/12/2009
More...
|
MorphoSys AG Receives Regulatory Approval to Start Phase 1b/2a Clinical Trial for MOR103 Program
11/9/2009
More...
|
Daval International Limited Awarded Orphan Drug Designation for Motor Neurone Disease Treatment
11/9/2009
More...
|
Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
11/6/2009
More...
|
Breast Cancer Vaccine Tests German Merck KGaA (MKGAF.PK)'s $1 Billion Strategy
11/5/2009
More...
|
European Medicines Evaluation Agency Grants Tikomed Orphan Drug Designation for IBSOLVMIR
11/3/2009
More...
|
ExonHit Therapeutics Inc. Presents New Clinical Advances on Its Alzheimer’s Diagnostic and Therapeutic Programs
10/30/2009
More...
|
Bayer HealthCare Pharmaceuticals (BAY) Presents Florbetaben Phase II Study Results at World Congress of Neurology
10/30/2009
More...
|
Mycenax Biotech Finishes Phase II Trial of Biosimilar Drug
10/28/2009
More...
|
Argos Therapeutics, Inc. Presents Positive Phase 2 Viral Load and Immune Response Data for Arcelis(TM) HIV Program at the AIDS Vaccine 2009 Conference
10/21/2009
More...
|
Bionor Immuno Release: Researchers Find That Vacc-4x Therapeutic Peptide-Based HIV Vaccine Increases CD4 T-Cells in Chronically Infected HIV-1 Patients on Antiretroviral Therapy (ART)
10/21/2009
More...
|
Crucell N.V. (CRXL) Rabies Monoclonal Antibody Combination: Positive Results Philippines Phase II Study Presented at RITA Conference
10/20/2009
More...
|
Action Pharma in new Phase II Clinical Trial
10/20/2009
More...
|
Biogen Idec, Inc. (California) (BIIB) and Biovitrum AB Announce Decision to Advance Long-Acting Hemophilia B Therapy into a Registrational Trial
10/19/2009
More...
|
BioAlliance Pharma Announces Phase I Trial for Fentanyl Lauriad(R) and the Submission of a Clonidine Lauriad(R) Phase II Clinical Trial Application
10/12/2009
More...
|
MediGene AG (DX:MDG) Successfully Completes Patient Recruitment Into Endotag(TM)-1 Phase II Breast Cancer Trial
10/9/2009
More...
|
Vantia Therapeutics's VA111913 Enters Phase II Proof-of-Concept Trials for Dysmenorrhoea
10/6/2009
More...
|
R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023
10/6/2009
More...
|
Immutep S.A. Announces New Interim Results In Phase I/II Chemoimmunotherapy Trial In Breast Cancer
10/6/2009
More...
|
LifeCycle Pharma Announces Positive Results from a 12 Month Extension Phase of the Phase 2 Clinical Study of LCP-Tacro™ Once Daily in Stable Liver Transplant Patients
9/29/2009
More...
|
Addex Pharmaceuticals (ADXN.SW) Completes Enrollment of First Mid-Stage Clinical GERD Trial
9/28/2009
More...
|
Morphotek Inc.: Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects
9/24/2009
More...
|
Bayer Corporation (BAY) (JOBS), Onyx Pharmaceuticals, Inc. (ONXX)'s Contested Kidney Cancer Drug Shows Benefit
9/23/2009
More...
|
Bayer Corporation (BAY), Onyx Pharmaceuticals, Inc. (ONXX) Pill Beats Hopes in Breast Cancer Test
9/23/2009
More...
|
BioInvent Updates On The Progress Of The Phase II Trial Of The Long Acting Anticoagulant TB-402
9/23/2009
More...
|
MagForce Nanotechnologies Completes Patient Recruitment for Pivotal Glioblastoma Study
9/22/2009
More...
|
Innate Pharma Reports Phase II Clinical Data With Iph 1101 In Oncology
9/21/2009
More...
|
Sosei Group Corporation: QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting
9/16/2009
More...
|
Cytheris SA Announces Interim Data from INSPIRE Study Showing Interleukin-7 (CYT107) Induces Dose-Dependent and Sustained Increase of CD4 T Cells in Chronic HIV-Infected Patients
9/15/2009
More...
|
AiCuris' Novel HCMV Compound Shows Good Tolerability And Efficacy In Phase II Study
9/15/2009
More...
|
Argenta Discovery Ltd. Publishes Positive Data From a Phase II Proof of Concept Trial with Co-Administration of Inhaled ADC4022 Plus Budesonide Study in COPD
9/15/2009
More...
|
ExonHit Therapeutics Inc. Presents Promising First Patient Results For EHT 0202, Its Alzheimer's Candidate Drug
9/14/2009
More...
|
Kamada Ltd. Presents Data on Inhaled Alpha-1 Antitrypsin in Cystic Fibrosis Patients at the European Respiratory Society Meeting 2009, Vienna
9/14/2009
More...
|
FDA and European Medicines Evaluation Agency Grant Orphan Drug Designation for ANTISENSE PHARMA GmbH's Investigational Drug Trabedersen in Pancreatic Carcinoma
9/14/2009
More...
|
Kenta Biotech Reports Phase IIa Data with Lead Candidate Panobacumab in Hospital-Acquired Pneumonia
9/14/2009
More...
|
Addex Pharmaceuticals (ADXN.SW)' ADX10059 Has Potential For Parkinson's Disease Levodopa Induced Dyskinesia (PD-LID)
9/14/2009
More...
|
BioLineRx Ltd. Announces Positive Topline Results for BL-1020, a First in Class GABA Enhanced Antipsychotic for the Treatment of Schizophrenia
9/14/2009
More...
|
Can-Fite BioPharma Announces Positive Results from its Psoriasis Phase II Trial with CF101
9/8/2009
More...
|
PAION Announces Patient Recruitment for Phase IIa Study with its Short Acting Anesthetic/Sedative CNS 7056 Successfully Completed
9/8/2009
More...
|
Novavax, Inc. (NVAX) Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate; NVAX Shares Rise
9/1/2009
More...
|
Gene Signal and Collaborators Publish GS-101 Phase II Clinical Data Suggesting Safe and Effective Inhibition of Abnormal Ophthalmic Blood Vessel Growth
9/1/2009
More...
|
Mesoblast Limited Interview With MD Silviu Itescu On Angioblast - Progression of Four Phase 2 Trial Applications
9/1/2009
More...
|
Sanofi-Aventis (France) (SASY.PA): Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
8/31/2009
More...
|
Medgenics, Inc. Announces Patient Nearing Unprecedented 11 Months of Anemia Relief in Clinical Trial From Single Treatment of Biopump Tissue Technology; News Follows Significant Interest of Strategic Partner for New Application
8/27/2009
More...
|
Genmab A/S (GEN.CO) Announces Positive Top-Line Results for Arzerra(tm) in Front Line NHL
8/26/2009
More...
|
Ark Therapeutics's VEGF D Gene-Based Medicine To Commence Phase I/Iia Development In Refractory Angina
8/26/2009
More...
|
AiCuris To Present Phase II Data For HCMV Compound At ICAAC
8/26/2009
More...
|
Morria Biopharmaceuticals Plc Obtains Institutional Review Board Clearance to Conduct Phase II Study in Contact Dermatitis Patients Using MRX6, a Novel Topical Anti-Inflammatory Drug
8/25/2009
More...
|
US Department of Health and Human Services Grants Orphan Drug Status to BioCancell Therapeutics's Ovarian Cancer Drug
8/24/2009
More...
|
Shanghai University of Traditional Chinese Medicine's TCM Drug OK’d to Begin US Phase II Clinical Trials for Hepatitis C At University of California, San Diego (UCSD) By FDA
8/20/2009
More...
|
Forest Laboratories, Inc. (FRX) Announces Phase IIb Study Results For Oglemilast in Chronic Obstructive Pulmonary Disease
8/19/2009
More...
|
Mesoblast Limited World-First Allogeneic Stem Cell Trial For Treatment Of End-Stage Heart Failure Patients
8/7/2009
More...
|
Shin Nippon Biomedical Laboratories Release: First Report on Results of US Phase 2 Clinical Study of Intranasal Granisetron
8/4/2009
More...
|
Cytos Biotechnology AG Says Allergy Drug Meets Main Target In Study
7/31/2009
More...
|
BTG plc (BGC.L): AstraZeneca PLC (AZN) to Progress CytoFab(TM) into Phase IIb Study
7/29/2009
More...
|
Living Cell Technologies Ltd. Enrolls Patients Into New Zealand Diabetes Clinical Trial
7/22/2009
More...
|
ViroMed Receives US FDA Approval of Phase II Trial for VM202 to Treat Peripheral Artery Disease
7/21/2009
More...
|
ISENTRESS (raltegravir), from Merck & Co., Inc. (MRK) (JOBS), was as Effective as Efavirenz at Suppressing HIV Viral Load and Increasing CD4 Cell Counts in Treatment-Naïve Patients up to 144 Weeks When Used in Combination Therapy
7/20/2009
More...
|
Genmab A/S (GNMSF.PK) Announces Lift of Zalutumumab Partial Clinical Hold
7/17/2009
More...
|
Results of Phase I and Phase IIa Clinical Studies Confirm the Inhibitory Effect of Proprietary Ipsen's BIM23A760 First-in-Class “Chimeric” Compound on Growth Hormone, IGF-1 and Prolactin Levels
7/16/2009
More...
|
PAION: Phase Ib and IIa Studies of the Anesthetic/Sedative CNS 7056 on Track
7/15/2009
More...
|
Safety and Cognitive Stability Are Key Findings in Phase IIA Trial of New Alzheimer's Disease Treatment from Humanetics
7/13/2009
More...
|
Oxford BioMedica PLC (OXB.L) Announces Update on Phase I/II Study of ProSavin(R) in Parkinson's Disease
7/13/2009
More...
|
PRANA Biotechnology (PRAN) to Provide Update on PBT2 Efficacy data
7/10/2009
More...
|
Takeda Pharmaceutical Co. Ltd. (TKDG.DE), Millennium: The Takeda Oncology Company And Canbas Co., Ltd.: CBP501 Enters Phase II Trials for the Treatment of Non-Small Cell Lung Cancer
7/7/2009
More...
|
BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study with TB-402
7/6/2009
More...
|
Genetic Immunity, InPlay: Company Completes Patient Enrollment in Italian Phase II Trial of DermaVir Patch HIV Immunotherapeutic Nanomedicine
7/1/2009
More...
|
Innate Pharma Reports Positive Phase IIa Clinical Results For Iph 1101 In Type C Viral Hepatitis
6/29/2009
More...
|
MorphoSys AG Reports Filing for Phase 1b/2a Trial for its Lead Program MOR103 in Rheumatoid Arthritis
6/24/2009
More...
|
Crucell N.V. (CRXL) Announces Positive Results of Phase II Rabies Monoclonal Antibody Combination Clinical Study in Philippines
6/24/2009
More...
|
BioLineRx Ltd. Announces New Results Confirming the Mode of Action of Its Anti-Psychotic Drug- BL-1020
6/22/2009
More...
|
BioLineRx Ltd. Initiates Phase I/II Trial of BL-5010, a Novel Formulation for the Non Surgical Removal of Skin Lesions
6/22/2009
More...
|
Neovacs SA To Expand Clinical Testing Of Its TNF-? Kinoid Lead Product Candidate Following Positive Preliminary Findings From A Phase I/II Study
6/22/2009
More...
|
Neovasc Inc. (NVC) to Expand Clinical Testing of Its TNF-alpha Kinoid Lead Product Candidate Following Positive Preliminary Findings from a Phase I/II Study
6/22/2009
More...
|
Antisense Therapeutics Limited (ANP.AX) Drug ATL1101 Enhances Effect of Existing Chemotherapy Treatment on Prostate Tumors
6/18/2009
More...
|
ExonHit Therapeutics Inc. Announces Last Patient out for EHT 0202 Phase IIa Study in Alzheimer
6/16/2009
More...
|
Regeneron Pharmaceuticals, Inc. (REGN), Sanofi-Aventis (France) (SASY.PA) to Not Submit Ovarian Cancer Drug Data
6/12/2009
More...
|
Bristol-Myers Squibb Company (BMY): Orencia(R) (Abatacept) Demonstrates Consistent Safety And Effectiveness Over 7 Years
6/12/2009
More...
|
DuoCort AB: Successful Phase II/III Trial Of New Therapy For Adrenal Insufficiency
6/12/2009
More...
|
Genetic Immunity, InPlay: Company Completes Patient Enrollment in Phase II Trial of DermaVir Patch HIV Immunotherapeutic Nanomedicine Lead Product Candidate
6/11/2009
More...
|
Pfizer Inc. (PFE)'s (JOBS) Oral JAK-3 Inhibitor Demonstrates Statistically Significant Response For Patients with Rheumatoid Arthritis, New Phase 2 Studies Show
6/11/2009
More...
|
Kamada Ltd. Reports Positive Proof-of-Concept Data for Inhaled Alpha-1 Antitrypsin in Bronchiectasis
6/9/2009
More...
|
NicOx SA (NCOX.F) Publishes Results Of The Zest Phase 2 Study For Naproxcinod
6/9/2009
More...
|
GlaxoSmithKline (GSK)'s GLP-1 Diabetes Drug Beats Byetta in Test
6/9/2009
More...
|
Active Biotech AB Completes Patient Enrollment to TASQ Clinical Phase II study
6/8/2009
More...
|
TRION Pharma: Trifunctional Antibody Catumaxomab Kills Cancer Stem Cells
6/2/2009
More...
|
Bavarian Nordic (BAVA.CO) PROSTVAC(TM) Data Presented at the American Society of Clinical Oncology Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
6/2/2009
More...
|
Swissmedic Grants Approval for a Clinical Study of Neovacs SA's TNFa-kinoid Candidate for the Treatment of Crohn's Disease
6/2/2009
More...
|
Can-Fite BioPharma Completed Patient Enrollment for the Phase II Trial in Psoriasis With CF101
6/1/2009
More...
|
Cytokinetics, Inc. (CYTK) Announces Presentations of Data From Phase IIa Clinical Trials of CK-1827452 at the 2009 Heart Failure Congress of the European Society of Cardiology
6/1/2009
More...
|
Pivotal Study Results: ChemGenex Pharmaceuticals Limited (CXS.AX)'s Omacetaxine May Provide the First Viable Drug Treatment Option for Patients With a Highly Resistant Form of CML
6/1/2009
More...
|
Antisoma PLC (ASM.L) To Advance AS1411 In AML Based On Positive Phase II Data Presented At American Society of Clinical Oncology
5/29/2009
More...
|
ChemGenex Pharmaceuticals Limited (CXS.AX) to Present Pivotal Data in T315I Positive CML Patients as Oral Presentation at American Society of Clinical Oncology
5/15/2009
More...
|
Merrion Pharmaceuticals, Inc. Announces Preliminary Results On Phase II Orazol(tm) Study
5/15/2009
More...
|
Merck Serono Champions Personalized Cancer Care With Targeted Therapies
5/15/2009
More...
|
LifeCycle Pharma Achieved Strong Progress in its Pipeline
5/14/2009
More...
|
ERYtech Pharma Announces That It Has Started a Phase II Clinical Trial with GRASPA(R) as First-Line Treatment among Patients with Acute Lymphoblastic Leukaemia (ALL) Aged 55 and Older
5/14/2009
More...
|
Circassia Limited Begins Phase II Clinical Trial With Ragweed Allergy Therapy New ToleroMune(R) Treatment Extends Circassia's Clinical-Stage Portfolio
5/13/2009
More...
|
Studies of GARDASIL(R), Merck & Co., Inc. (MRK)'s Cervical Cancer Vaccine, and HPV 16 Vaccine Component of GARDASIL Presented at International Papillomavirus Conference
5/8/2009
More...
|
Ablynx Announces That Its vWF Nanobody(R) Programme Has Been Granted Orphan Drug Designation and Provides a Business Update for the First Quarter 2009
5/7/2009
More...
|
SYGNIS Pharma AG Starts Phase II Efficacy Trial Of AX200 For The Treatment Of Acute Ischemic Stroke
5/5/2009
More...
|
Ark Therapeutics's Trinam(R) Awarded Fast Track Status by FDA
5/5/2009
More...
|
Debiopharm Debio 025 in Hepatitis C Debiopharm Starts Phase IIb Study After Record Time Patient Randomisation
4/30/2009
More...
|
Addex Pharmaceuticals (ADXN.SW) Presents Data on ADX10059 at the Annual Meeting of the American Academy of Neurology
4/29/2009
More...
|
Mesoblast Limited Commences Clinical Program For Fusion Of Cervical Spine
4/28/2009
More...
|
Debiopharm Release: Debio 025 in Hepatitis C Debiopharm Presents Promising Phase IIa Results Showing Potent Antiviral Activity
4/28/2009
More...
|
Living Cell Technologies Ltd. New Zealand Pigs Free of Viruses
4/27/2009
More...
|
OctoPlus' Licensee Biolex Therapeutics Presents Locteron Phase IIa Results at EASL Conference
4/24/2009
More...
|
Medivir AB (MVIRb.F): New Phase IIa Data on TMC435 in Patients with Hepatitis C Presented at the Ongoing EASL - Meeting
4/24/2009
More...
|
Schering-Plough Corporation (SGP) Release: Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
4/23/2009
More...
|
Schering-Plough Corporation (SGP) Hepatitis C Drug Shines, But Anemia Seen; Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
4/23/2009
More...
|
Vertex Pharmaceuticals Incorporated (VRTX) to Present Data at EASL Suggesting Telaprevir’s Potential for Use in a Broad Range of HCV Patients and Highlighting the Company’s Expanded STAT-C Portfolio
4/22/2009
More...
|
Emergent BioSolutions (EBS) Release: New TB Vaccine Candidate Enters Phase IIb Proof-of-Concept Trial in South Africa
4/22/2009
More...
|
Teva Pharmaceutical Industries Limited (TEVA) to Present New Data on Its Innovative Therapies for Multiple Sclerosis and Parkinson’s Disease at the Upcoming 2009 American Academy of Neurology Annual Meeting
4/22/2009
More...
|
Circassia Limited's Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
4/21/2009
More...
|
Isotechnika Inc. (ISA.TO) Announces Positive 12 Month Data from PROMISE Trial
4/21/2009
More...
|
Hadasit Bio Holdings Portfolio Company Tolarex Ltd. to Commence Phase I/IIa Trial of a Treatment for GVHD
4/20/2009
More...
|
Palau Pharma Initiates A Phase II Clinical Trial Of Dersalazine Sodium In Mild To Moderate Ulcerative Colitis
4/20/2009
More...
|
Promising Interim Results from Hybrigenics' Inecalcitol Phase II in Combination with Taxotere(R) for Hormone-Refractory Prostate Cancer
4/17/2009
More...
|
Can-Fite BioPharma to Initiate Phase I/II Clinical Trial With CF102 for the Treatment of Liver Cancer
4/16/2009
More...
|
Genetic Immunity, InPlay: Second Phase II Clinical Trial Commences in Italy on Company's Lead Product Candidate DermaVir Patch HIV Vaccine
4/16/2009
More...
|
PAION Initiates Phase II Trial with its Anesthetic/Sedative CNS 7056
4/15/2009
More...
|
Evotec AG (EVTG.F) Reports Results of Phase II Proof-of-Concept Study With EVT 302
4/14/2009
More...
|
PAION And ErgoMed Report Full Data of CNS 5161 Phase IIa Study in Neuropathic Cancer Pain
4/9/2009
More...
|
Serentis Starts Phase II Trial with First-in-Class SRD441 for Eczema
4/7/2009
More...
|
Independent Study Corroborates PRANA Biotechnology (PRAN)'s Strategy to Treat Alzheimer's Disease Patients
4/1/2009
More...
|
Gentium S.p.A. Announces Preliminary Results from a Phase 2/3 European Pediatric Prevention Trial for Veno-Occlusive Disease at the European Group for Blood and Marrow Transplantation Annual Meeting
3/30/2009
More...
|
Medgenics, Inc.’s Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
3/27/2009
More...
|
Celtic Pharma Announces Successful Outcome Of Phase II Trial For Topical Treatment Of Onychomycosis
3/26/2009
More...
|
Starpharma Holdings Ltd Completes Patient Testing In Retention Of VivaGel Antiviral Activity Study
3/19/2009
More...
|
Merck Serono Expands Cilengitide Development Program
3/16/2009
More...
|
AGI Therapeutics plc Announces Positive Phase II AGI-004 Proof of Concept Study
3/12/2009
More...
|
Auris Medical AG Initiating Phase IIb Clinical Trial With AM-101
3/12/2009
More...
|
Arana Therapeutics Successfully Completes Phase II Psoriasis Study; ART621 Meets Primary Endpoint
3/9/2009
More...
|
Serentis Starts Phase II Clinical Trial in Pruritus of Skin Disease
3/4/2009
More...
|
immatics biotechnologies GmbH Completes Patient Recruitment In Phase II Study With Cancer Vaccine IMA901 For Renal Cell Cancer
3/3/2009
More...
|
Millennium: The Takeda Oncology Company Initiates Two Phase II Trials of Novel Aurora A Kinase Inhibitor
3/3/2009
More...
|
Bavarian Nordic (BAVA.CO) Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
3/3/2009
More...
|
Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
3/3/2009
More...
|
Astellas Pharma Inc. And XenoPort, Inc. (XNPT) Announce Positive Results from Phase 2 Trial of ASP8825/XP13512 in Japan for Restless Legs Syndrome
3/2/2009
More...
|
Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects
2/26/2009
More...
|
Karo Bio AB: Eprotirome Study Selected for Oral Presentation at the American College of Cardiology Meeting
2/25/2009
More...
|
Mesoblast Limited First Group Of Heart Failure Patients Treated With "Off-The-Shelf" Adult Stem Cells Successfully Pass Key Safety Milestone
2/25/2009
More...
|